NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to market Axiogenesis' mouse-induced pluripotent stem cell-derived cardiomyocytes and smooth muscle cells for preclinical cardiotoxicity screening.
The Sigma Life Science business of Sigma-Aldrich will offer the products as ready-to-order cells, application-specific kits, and custom services. Financial and other terms of the agreement were not disclosed.
The deal announced today builds on an earlier agreement signed by Sigma-Aldrich granting it worldwide rights to Kyoto University's induced pluripotent stem cell patent portfolio.
"This partnership deepens Sigma Life Science's commitment to alleviate critical deficiencies in ADME/toxicology screening and preclinical development through application of iPS cell technology recently licensed from Kyoto University, CompoZr Zinc Finger Nucleases, and the SAGEspeed Custom Animal Model Development program," John Listello, market segment manager of stem cell research and regenerative medicine at Sigma Life Science, said in a statement.